OTC: BRCTF - BioArctic AB (publ)

Rentabilité sur six mois: +41.7%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions BioArctic AB (publ)


À propos de l'entreprise BioArctic AB (publ)

BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. It also develops ABBV-0805, for treating Parkinson's disease.

plus de détails
In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders. Further, it develops BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814 andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, BAN0805, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета sek
Сайт https://www.bioarctic.se
Цена ао 23.02
Changement de prix par jour: 0% (22.608)
Changement de prix par semaine: -6.77% (24.25)
Changement de prix par mois: +12.96% (20.015)
Changement de prix sur 3 mois: +31.25% (17.2255)
Changement de prix sur six mois: +41.7% (15.955)
Changement de prix par an: +6.39% (21.25)
Evolution du prix sur 3 ans: 0% (22.608)
Evolution du prix sur 5 ans: 0% (22.608)
Evolution des prix sur 10 ans: 0% (22.608)
Evolution des prix depuis le début de l'année: +23.54% (18.3)

Sous-estimation

Nom Signification Grade
P/S 69.53 1
P/BV 19.99 1
P/E 99.75 1
EV/EBITDA -92.9 0
Total: 1.13

Efficacité

Nom Signification Grade
ROA, % -15.41 0
ROE, % -18.24 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 1.17

Devoir

Nom Signification Grade
Debt/EBITDA -0.289 10
Total: 9

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 312.77 10
Rentabilité Ebitda, % 151.96 10
Rentabilité EPS, % 160.36 10
Total: 10



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Gunilla Osswald Ph.D. President & CEO 8.2M 1961 (64 année)
Dr. Pär Gellerfors Co-Founder, Senior VP of Business Strategy & Director 321k 1947 (78 années)
Prof. Lars Lannfelt Co-Founder, Senior VP of Medical science & Director 2.45M 1949 (76 années)
Mr. Anders Martin-Lof M.B.A., M.Sc. Chief Financial Officer N/A 1971 (54 année)
Mr. Christer Möller VP of Pre-Clinical Development & Chief Scientific Officer N/A 1959 (66 années)
Mr. Oskar Bosson VP and Head of IR & Communication N/A 1976 (49 années)
Mr. Leif Gallo LL.M. General Counsel and Head of Legal & IP N/A 1959 (66 années)
Mr. Harald Borgeke Head of Public Affairs N/A
Ms. Frida Lekander Head of Marketing N/A
Ms. Johanna Fälting Chief Research Officer & Head of Research 1972 (53 année)

Adresse: Sweden, Stockholm, Warfvinges vag 35 - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.bioarctic.se